Changeflow GovPing Healthcare & Life Sciences Phase 3 CBD Trial, Jiu-Jitsu Athletes, Pain, Sleep
Routine Notice Added Final

Phase 3 CBD Trial, Jiu-Jitsu Athletes, Pain, Sleep

Favicon for clinicaltrials.gov ClinicalTrials.gov - Phase 3 Trials by Start Date
Published
Detected
Email

Summary

A Phase 3 clinical trial (NCT07552974) registered by the NIH on ClinicalTrials.gov is investigating the effects of CBD on pain and sleep outcomes in Jiu-Jitsu athletes. The trial was started on September 1, 2022, and is classified as an interventional study examining a botanical CBD intervention for athletic performance and recovery. This registration provides public transparency on the trial's scope and participant population of 52 participants.

Published by NIH on clinicaltrials.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov - Phase 3 Trials by Start Date for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 21 changes logged to date.

What changed

A new Phase 3 clinical trial (NCT07552974) has been registered on ClinicalTrials.gov by the NIH, investigating CBD (cannabidiol) as an intervention for pain and sleep outcomes specifically in Jiu-Jitsu athletes. The trial enrolled 52 participants and began on September 1, 2022.

Pharmaceutical companies and clinical investigators conducting cannabis-derived product research in athletic populations should note this trial as a reference for CBD study design and outcome measurement. Healthcare providers working with combat sport athletes may find relevance in emerging CBD efficacy data for pain and sleep management.

Archived snapshot

Apr 28, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov - Phase 3 Trials by Start Date

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
September 1st, 2022
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Clinical investigators Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 4453 Cannabis 6211 Healthcare Providers
Activity scope
Clinical trials Drug research Athletic medicine
Geographic scope
United States US

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Topics
Pharmaceuticals Healthcare Cannabis

Get alerts for this source

We'll email you when ClinicalTrials.gov - Phase 3 Trials by Start Date publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!